{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:48:59Z","timestamp":1780458539478,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.pharma.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T09:48:06Z","timestamp":1336729686000},"page":"139-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration"],"prefix":"10.1016","volume":"70","author":[{"given":"M.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Roumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Despiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Astier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2012.03.006_bib0005","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0010","first-page":"804","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"91","author":"Bock","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.pharma.2012.03.006_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ophtha.2009.06.048","article-title":"Anti-angiogenic approaches to age-related macular degeneration today","volume":"116","author":"Bressler NM","year":"2009","journal-title":"Ophtalmology"},{"key":"10.1016\/j.pharma.2012.03.006_bib0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/OPTH.S2094","article-title":"Age-related macular degeneration: current treatments","volume":"3","author":"Hubschman","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.pharma.2012.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovacularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.pharma.2012.03.006_bib0030","doi-asserted-by":"crossref","unstructured":"Schwartz SG, Flynn Jr HW. Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res; 2007, Article ID 52487, doi:10.1155\/2007\/52487.","DOI":"10.1155\/2007\/52487"},{"key":"10.1016\/j.pharma.2012.03.006_bib0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/OPTH.S7698","article-title":"Bevacizumab (Avastin\u00ae) for the management of anterior chamber neovascularisation and neovascular glaucoma","volume":"3","author":"Brouzas","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.pharma.2012.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophtalmol"},{"key":"10.1016\/j.pharma.2012.03.006_bib0045","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","year":"2011","journal-title":"New Eng J Med"},{"key":"10.1016\/j.pharma.2012.03.006_bib0050","unstructured":"http:\/\/www.aao.org\/newsroom\/release\/20110428.cfm. Acc\u00e9d\u00e9 le 3\u00a0janvier 2012."},{"key":"10.1016\/j.pharma.2012.03.006_bib0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","article-title":"Six-month stability of bevacizumab (Avastin\u00ae) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing","volume":"26","author":"Bakri","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.pharma.2012.03.006_bib0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophtalmol Vis Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0065","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","article-title":"High molecular weight aggregates in repackaged bevacizumab","volume":"30","author":"Kahook","year":"2010","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.pharma.2012.03.006_bib0070","first-page":"37","article-title":"Thermal stability of two monoclonal antibodies: cetuximab and bevacizumab","volume":"2","author":"Paul","year":"2008","journal-title":"Eur J Oncol Pharm"},{"key":"10.1016\/j.pharma.2012.03.006_bib0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pharma.2009.05.008","article-title":"Mechanically-induced aggregation of the monoclonal antibody cetuximab","volume":"67","author":"Lahlou","year":"2009","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2012.03.006_bib0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpb.2004.12.004","article-title":"Induction and analysis of aggregates in a liquid igG1-antibody formulation","volume":"59","author":"Mahler","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.pharma.2012.03.006_bib0085","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1097-0282(200009)54:3<168::AID-BIP20>3.0.CO;2-9","article-title":"Static and dynamic light scattering from aggregating particles","volume":"54","author":"Bloomfield","year":"2000","journal-title":"Biopolymers"},{"key":"10.1016\/j.pharma.2012.03.006_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2012.03.006_bib0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2012.03.006_bib0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","article-title":"Aggregation, stability and formulation of human antibody therapeutics","volume":"84","author":"Lowe","year":"2011","journal-title":"Adv Prot Chem Struct Biol"},{"key":"10.1016\/j.pharma.2012.03.006_bib0105","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving force in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2012.03.006_bib0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-1656(00)00236-4","article-title":"Stability and stabilization of globular proteins in solution","volume":"79","author":"Jaenicke","year":"2000","journal-title":"J Biotechnol"},{"key":"10.1016\/j.pharma.2012.03.006_bib0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1515\/BC.1999.114","article-title":"Elementary steps in protein folding","volume":"380","author":"Bieri","year":"1999","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharma.2012.03.006_bib0120","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jps.20619","article-title":"Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor","volume":"95","author":"Thirumangalathu","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0141-8130(96)01150-6","article-title":"Destabilization of human serum albumin by polyethylene glycols studied by thermodynamical equilibrium and kinetic approaches","volume":"20","author":"Farruggia","year":"1997","journal-title":"Int J Biol Macromolecules"},{"key":"10.1016\/j.pharma.2012.03.006_bib0130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jps.20753","article-title":"Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability","volume":"96","author":"Harn","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0135","first-page":"175","article-title":"Thermal stability: a means to assure tertiary structure in therapeutic proteins","volume":"30","author":"Cauchy","year":"2002","journal-title":"Biol J Int Assoc Biol Stand"},{"key":"10.1016\/j.pharma.2012.03.006_bib0140","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/jps.10439","article-title":"Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study","volume":"92","author":"Kuelzo","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1432-1033.1978.tb12622.x","article-title":"Second derivative spectroscopy of proteins. A method for the quantitative determination of aromatic amino acids in proteins","volume":"90","author":"Balestrieri","year":"1978","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharma.2012.03.006_bib0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0005-2795(79)90203-4","article-title":"Estimation of state and amount of phenylalanine residues in proteins by second derivative spectrophotometry","volume":"580","author":"Ichikawa","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharma.2012.03.006_bib0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0003-2697(82)90512-7","article-title":"Simultaneous determination of tyrosine and tryptophan residues in proteins by second derivative spectroscopy","volume":"126","author":"Servillo","year":"1982","journal-title":"Anal Biochem"},{"key":"10.1016\/j.pharma.2012.03.006_bib0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1745-7270.2007.00320.x","article-title":"Fourier transform infrared spectroscopic analysis of protein secondary structures","volume":"39","author":"Kong","year":"2007","journal-title":"Acta Biochimica Biophysica Sinica"},{"key":"10.1016\/j.pharma.2012.03.006_bib0165","series-title":"Fundamentals of Fourier transform infrared spectroscopy","author":"Smith","year":"1996"},{"key":"10.1016\/j.pharma.2012.03.006_bib0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-3233(08)60528-8","article-title":"Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins","volume":"38","author":"Krimm","year":"1986","journal-title":"Adv Protein Chem"},{"key":"10.1016\/j.pharma.2012.03.006_bib0175","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0076-6879(86)30015-6","article-title":"Resolution-enhanced Fourier transform infrared spectroscopy of enzymes","volume":"130","author":"Byler","year":"1986","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.pharma.2012.03.006_bib0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0731-7085(97)00178-7","article-title":"Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion","volume":"16","author":"Moorhouse","year":"1997","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2012.03.006_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.03.030","article-title":"A simple and reproducible approach to characterize protein stability using rheology","volume":"374","author":"Liu","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2012.03.006_bib0190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0731-7085(96)01721-9","article-title":"The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody","volume":"14","author":"Usami","year":"1996","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2012.03.006_bib0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchromb.2004.12.033","article-title":"Non-enzymatic hinge region fragmentation of antibodies in solution","volume":"818","author":"Cordoba","year":"2005","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.22739","article-title":"Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions","volume":"101","author":"Sreedhara","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(85)91892-6","article-title":"Pillution of insulin with silicone oil, a hazard of disposable plastic syringes","volume":"1","author":"Chanteleau","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2012.03.006_bib0210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2337\/diacare.9.6.672","article-title":"Silicone oil release from disposable insulin syringes","volume":"9","author":"Chanteleau","year":"1986","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2012.03.006_bib0215","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jps.20321","article-title":"Silicone oil-induced aggregation of proteins","volume":"94","author":"Jones","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0220","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/jps.21719","article-title":"Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution","volume":"98","author":"Thirumangalathu","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2012.03.006_bib0225","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0006-3495(00)76602-1","article-title":"The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein","volume":"78","author":"Vermeer","year":"2000","journal-title":"Biophys J"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:29:55Z","timestamp":1757719795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450912000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0003450912000557"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2012.03.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2012.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}